Zoetis Inc.
Zoetis Inc. Enters into New Revolving Credit Agreement and Terminates Prior Agreement
Summary
On August 27, 2025, Zoetis Inc. entered into a new five-year $1.25 billion senior unsecured revolving credit facility with a syndicate of banks, replacing its existing revolving credit facility. The Company also terminated its prior credit agreement dated December 21, 2022, which was scheduled to expire in December 2027. The new Credit Agreement provides for the right to increase the commitments to up to $1.75 billion, subject to certain conditions. It contains financial covenants, affirmative and negative covenants, and customary events of default. A copy of the new Credit Agreement is attached as Exhibit 10.1.
Profitelligence Alerts
Get alerts for ZTS
Be first to know when Zoetis Inc. files with the SEC.
Filing Categories
Advertisement
About Zoetis Inc.
Zoetis Inc. is a global leader in the animal healthcare sector, specializing in the development, manufacture, and commercialization of a diverse range of medicines and vaccines for pets and livestock. Originally part of Pfizer, Zoetis spun off in 2013 and has solidified its position as a key player in the industry. The company's portfolio includes products aimed at veterinarians and livestock producers, supporting health and productivity across various animal species. Zoetis's impact is significant in both the companion animal market, which is driven by increasing pet ownership and rising expenditure on pet care, and the livestock market, which benefits from enhancements in productivity and disease management. Zoetis operates in over 100 countries, continuously investing in research and innovation to address the evolving needs of animal health. Its strategic initiatives and partnerships contribute to building a sustainable future for the animal health industry, bolstering Zoetis’s reputation and relevance in the global market.
Official SEC Documents
Advertisement